Pulse nav.journalClub Débats actifs Tendances Explorer Chercheurs

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Accueil Explorer nav.journalClub Tendances

⌘+K

© Synapse Social LLC, 2026

Politique de confidentialité

Cost-Effectiveness of Temozolamide for Treatment of Glioblastoma Multiforme in India | Synapse

January 15, 2021Open Access

Cost-Effectiveness of Temozolamide for Treatment of Glioblastoma Multiforme in India

Key Points

Key points are not available for this paper at this time.

Abstract

Temozolamide is not cost-effective for treatment of patients with GBM in India. This evidence should be used while framing guidelines for treatment and price regulation.

Demander à l'IA

Like

Bookmark

Share

View Full Paper

Demander à l'IA

Like

Bookmark

Share

View Full Paper

Cite This Study

Gupta et al. (Fri,) studied this question.

synapsesocial.com/papers/69e7489d67c6782a4be40b0f https://doi.org/https://doi.org/10.1200/go.20.00288

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies2009 · 915 citations
2Making choices in health: who guide to cost-effectiveness analysis2004 · 1,279 citations
3Subgroup Economic Analysis for Glioblastoma in a Health Resource-Limited Setting2012 · 37 citations
4Cost–effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme2009 · 24 citations
5Establishing reference costs for the health benefit packages under universal health coverage in India: cost of health services in India (CHSI) protocol2020 · 53 citations